Challenges and successes for the grantees and the Technical Advisory Group of WHO's influenza vaccine technology transfer initiative

Vaccine

Volumn 34, Issue 45, 2016, Pages 5420-5424

  Grohmann, Gary ^a   Francis, Donald P ^b   Sokhey, Jaspal ^c   Robertson, James ^d  

^a Environmental Pathogens   (Australia)

^b Global Solutions for Infectious Diseases   (United States)

^c Consultant in Vaccinology ^*  (India)

^d Consultant in Virology ^*  (United Kingdom)

Author keywords

Influenza; Less developed countries; Technology transfer; Vaccine manufacture

Indexed keywords

INFLUENZA VACCINE;

ARTICLE; DEVELOPING COUNTRY; FUNDING; HUMAN; PANDEMIC INFLUENZA; PRIORITY JOURNAL; TECHNOLOGY; VACCINE PRODUCTION; WORLD HEALTH ORGANIZATION; INFLUENZA; PANDEMIC; PHARMACEUTICS; TRENDS;

DEVELOPING COUNTRIES; HUMANS; INFLUENZA VACCINES; INFLUENZA, HUMAN; PANDEMICS; TECHNOLOGY TRANSFER; TECHNOLOGY, PHARMACEUTICAL; WORLD HEALTH ORGANIZATION;

EID: 84992554861     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2016.07.047     Document Type: Article

References (14)

1. [1] World Health Organization. Sixty-fourth World Health Assembly (WHA64.5). Pandemic influenza preparedness: sharing of influenza viruses and access to vaccines and other benefits. < http://apps.who.int/iris/bitstream/10665/44796/1/9789241503082_eng.pdf>; 2011[accessed 20.06.16].
2. [2] World Health Organization. WHO's Global Influenza Surveillance and Response System (GISRS). < http://www.who.int/influenza/gisrs_laboratory/en/>; 2016 [accessed 20.06.16].
3. [3] World Health Organization. Global pandemic influenza action plan to increase vaccine supply. < http://apps.who.int/iris/bitstream/10665/69388/1/WHO_IVB_06.13_eng.pdf>; 2006 [accessed 20.06.16].
4. [4] Francis, D.P., Grohmann, G., WHO influenza vaccine technology transfer initiative: role and activities of the technical advisory group. Vaccine 29S1 (2011), A45–A47.
5. [5] Hendriks, J., Holleman, M., de Boer, O., de Jong, P., Luytjes, W., An international technology platform for influenza vaccines. Vaccine 29S1 (2011), A8–A11.
6. [6] Collin, N., Dubois, P.M., The Vaccine Formulation Laboratory: a platform for access to adjuvants. Vaccine 29S1 (2011), A37–A39.
7. [7] World Health Organization. Influenza. < http://www.who.int/influenza/gisrs_laboratory/meetings/en/>; 2016 [accessed 20.06.16].
8. [8] World Health Organization. Influenza. < http://www.who.int/influenza/vaccines/virus/4thmtg_improve_vaccine_virus_selection/en/>; 2016 [accessed 20.06.16].
9. [9] World Health Organization. Influenza Vaccine Response during the Start of a Pandemic. Report of a WHO Informal Consultation held in Geneva, Switzerland, 29 June–1 July 2015. < http://www.who.int/influenza/resources/publications/influenzavaccineresponse_meeting01/en/>; 2015 [accessed 20.06.16].
10. [10] Convention on Biological Diversity, United Nations. Nagoya protocol on access to genetic resources and the fair and equitable sharing of benefits arising from their utilization. < https://www.cbd.int/abs/doc/protocol/nagoya-protocol-en.pdf>; 2011 [accessed 20.06.16].
11. [11] US Food and Drug Administration. Flublok. < http://www.fda.gov/BiologicsBloodVaccines/Vaccines/ApprovedProducts/ucm335836.htm>; 2016 [accessed 20.06.16].
12. [12] World Health Organization. Technology transfer: adjuvants. < http://www.who.int/phi/implementation/techtransfer_vaccines_adjuvants/en/>; 2016 [accessed 20.06.16].
13. [13] Zehrung, D., Jarrahian, C., Wales, A., Intradermal delivery for vaccine dose sparing: overview of current issues. Vaccine 31:34 (2013), 3392–3395.
14. [14] PATH. Dose-sparing and intradermal applications. < http://sites.path.org/vpdt/dose-sparing-and-intradermal-applications/>; 2016 [accessed 20.06.16].